MRTX News and Press, Mirati Therapeutics Inc. From 11/08/22

Mirati Therapeutics press release ( NASDAQ: MRTX ): Q3 GAAP EPS of -$3.09 beats by $0.40 . Revenue of $5.4M (-92.5% Y/Y) beats by $4.03M . MRTX's revenue of $71.8M in Q3 last year was due to the recognition of $66.6M of revenue associated with the transfer...

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial r...

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team PR Newswire Charles M. Baum , M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a d...

Mirati Therapeutics ( NASDAQ: MRTX ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, after market close. The consensus EPS Estimate is -$3.48 and the consensus Revenue Estimate is $1.37M (-98.1% Y/Y). Over the last 3 months, EPS estimates have se...

Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib ...

Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce f...

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation PR Newswire SAN DIEGO and LOS ANGELES , Oct....

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Summary Amgen's KRAS targeting drug Lumakras has now been approved in the US and Europe, making $77m sales in Q222. Mirati Therapeutics also has a KRAS targeting drug which may well win approval in December in the same indication as Lumakras - NSCLC. The companies' drugs can b...

Piper Sandler launched its coverage on oncology-focused biotech Mirati Therapeutics, Inc. ( NASDAQ: MRTX ) with an Overweight rating and a $110 per share target on Thursday, citing the potential of its experimental cancer therapy adagrasib compared to a rival drug from Amgen ( ...